Plain-English translation of NCT07483099 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining mirikizumab with another medication called works better than mirikizumab alone for treating moderate to severe Crohn's disease. You would be randomly assigned to receive either the combination treatment or mirikizumab by itself. The trial lasts about 62 weeks and will measure how well the treatment works and how safe it is.
Crohn's disease can be challenging to treat, and some patients don't respond well enough to existing therapies. This study is exploring whether adding a second medication to this treatment might help more patients achieve better control of their symptoms.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one receiving intravenous infusions of mirikizumab alone, or the other receiving both an oral medication (taken by mouth) and intravenous mirikizumab together. In the first phase, you'll receive the IV treatment; if you respond well, the second phase switches to injections under the skin. The entire study lasts approximately 62 weeks with multiple visits to monitor your progress and safety.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States